| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Cash Flows from Operating Activities | ||||||
Net loss | ||||||
-82,372 | -95,357 | -91,863 | -91,148 | - | - | |
Net loss | ||||||
- | - | - | - | -39,209 | -17,014 | |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
4,309 | 4,369 | 3,426 | - | - | - | |
Depreciation and amortization | ||||||
- | - | - | 2,003 | 634 | 240 | |
Amortization of intangible assets | ||||||
554 | 584 | 559 | 549 | 89 | 0 | |
Impairment of property and equipment | ||||||
1,177 | - | - | - | - | - | |
Impairment of intangible assets | ||||||
5,006 | 3,992 | - | - | - | - | |
Non-cash lease expense | ||||||
947 | - | - | - | - | - | |
Accretion of discounts and amortization of premiums on marketable securities | ||||||
1,670 | 1,067 | -621 | -1,831 | -725 | - | |
Realized gain on investments | ||||||
4 | - | - | - | - | - | |
Stock-based compensation | ||||||
12,439 | 17,474 | 16,376 | 15,006 | 8,430 | 570 | |
Excess tax benefit from stock-based compensation | ||||||
- | - | - | 4,444 | - | - | |
Loss from remeasurement of fair value of contingent consideration | ||||||
73 | 635 | 2,824 | 400 | - | - | |
Loss from remeasurement of fair value of warrants | ||||||
- | - | - | - | 26,077 | 566 | |
Gain from changes in the fair value of preferred stock derivative liability | ||||||
- | - | - | - | - | 1,475 | |
Gain on extinguishment of convertible promissory notes | ||||||
- | - | - | - | - | 3,553 | |
Non-cash interest expense related to convertible promissory notes payable | ||||||
- | - | - | - | - | 2,380 | |
Loss on disposal of property and equipment | ||||||
-6 | -27 | -9 | -15 | - | - | |
Deferred income tax | ||||||
-2,450 | -146 | 6,180 | -7,800 | - | - | |
Changes in operating assets and liabilities: | ||||||
Payment of contingent consideration | ||||||
- | 3,322 | - | - | - | - | |
Accounts receivable | ||||||
-11,695 | 11,048 | -149 | -3,708 | 1,693 | 2,796 | |
Income tax receivable | ||||||
- | -17,495 | 17,495 | - | - | - | |
Prepaid expenses and other assets | ||||||
-526 | -1,006 | -1,535 | -3,487 | 2,654 | 1,117 | |
Accounts payable | ||||||
-799 | 533 | -1,206 | -2,851 | 1,537 | 1,681 | |
Deferred revenue | ||||||
-14,758 | 288 | -14,944 | -15,068 | - | - | |
Deferred revenue | ||||||
- | - | - | - | 157,064 | 35,962 | |
Accrued clinical trial and manufacturing expenses | ||||||
1,730 | -3,300 | 924 | -745 | 2,172 | 2,460 | |
Accrued expenses and other liabilities | ||||||
-1,583 | -922 | 4,049 | 8,981 | 1,638 | 1,461 | |
Operating lease liabilities | ||||||
-334 | - | - | - | - | - | |
Net cash used in operating activities | ||||||
-65,508 | -68,759 | -88,856 | -86,076 | - | - | |
Cash Flows from Investing Activities | ||||||
Net cash used in operating activities | ||||||
- | - | - | - | 154,810 | 19,365 | |
Purchase of marketable securities | ||||||
283,097 | 226,953 | 260,435 | 359,500 | 359,378 | - | |
Proceeds from maturities of marketable securities | ||||||
282,594 | 268,684 | 354,530 | 351,322 | 77,885 | - | |
Purchase of property and equipment | ||||||
1,260 | 2,365 | 5,154 | 23,887 | 2,174 | 782 | |
Proceeds from sale of property and equipment | ||||||
- | 41 | - | - | - | - | |
Net cash provided by (used in) investing activities | ||||||
-1,763 | 39,407 | 88,941 | -32,065 | - | - | |
Cash Flows from Financing Activities | ||||||
Payment of contingent consideration | ||||||
- | 3,481 | - | - | - | - | |
Acquisition, net of cash acquired | ||||||
- | - | - | - | 14,321 | - | |
Net cash (used in) provided by investing activities | ||||||
- | - | - | - | -297,988 | -782 | |
Proceeds from issuance of common stock, net of offering costs | ||||||
- | - | 78,991 | 36,806 | 150,283 | - | |
Excess tax benefit from stock-based compensation | ||||||
- | - | - | 4,444 | - | - | |
Deferred offering costs | ||||||
- | - | - | - | - | 1,092 | |
Proceeds from issuance of convertible promissory note payable to related parties | ||||||
- | - | - | - | - | 308 | |
Repayment of note payable to related party | ||||||
- | - | - | - | - | 200 | |
Proceeds from issuance of convertible preferred stock, net of issuance costs | ||||||
- | - | - | - | 22,522 | 93,276 | |
Proceeds from exercise of stock options | ||||||
530 | 1,457 | 2,235 | 1,000 | 801 | 49 | |
Proceeds from employee stock purchase plan | ||||||
213 | 529 | 828 | 835 | 572 | - | |
Net cash provided by financing activities | ||||||
743 | -1,495 | 82,054 | 43,085 | - | - | |
Effect of exchange rate changes | ||||||
-158 | -457 | 543 | - | - | - | |
Net cash provided by financing activities | ||||||
- | - | - | - | 174,178 | 92,341 | |
Net increase (decrease) in cash, cash equivalents and restricted cash | ||||||
-66,686 | -31,304 | 82,682 | -75,056 | - | - | |
Supplemental Disclosure | ||||||
Cash paid for interest | ||||||
- | - | - | - | - | 18 | |
Cash paid for taxes | ||||||
- | - | 1,106 | 22,400 | - | - | |
Supplemental Disclosure of Non-Cash Investing and Financing Activities | ||||||
Stock issued in connection with business acquisition | ||||||
- | - | - | - | 11,452 | - | |
Conversion of convertible preferred stock to common stock | ||||||
- | - | - | - | 164,964 | - | |
Reclassification of warrant liabilities to additional paid-in capital | ||||||
- | - | - | - | 27,066 | - | |
Purchase of property and equipment in accounts payable and accrued liabilities | ||||||
31 | 331 | 2,790 | 447 | 692 | - | |
Reconciliation of Cash, Cash Equivalents and Restricted Cash | ||||||
Net increase (decrease) in cash and cash equivalents | ||||||
- | - | - | - | 31,000 | 110,924 | |